First Light Asset Management LLC lowered its holdings in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Free Report) by 31.5% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 1,560,991 shares of the company’s stock after selling 717,949 shares during the period. Centessa Pharmaceuticals accounts for approximately 5.6% of First Light Asset Management LLC’s holdings, making the stock its 5th largest position. First Light Asset Management LLC owned about 1.05% of Centessa Pharmaceuticals worth $62,003,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of the business. TD Waterhouse Canada Inc. acquired a new stake in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $25,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Centessa Pharmaceuticals during the 4th quarter worth approximately $36,000. T. Rowe Price Investment Management Inc. increased its holdings in shares of Centessa Pharmaceuticals by 7,580.0% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock worth $39,000 after acquiring an additional 1,516 shares during the last quarter. Wells Fargo & Company MN increased its holdings in shares of Centessa Pharmaceuticals by 42.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock worth $85,000 after acquiring an additional 1,008 shares during the last quarter. Finally, Knott David M Jr bought a new stake in Centessa Pharmaceuticals in the 4th quarter valued at $100,000. Institutional investors and hedge funds own 82.01% of the company’s stock.
Centessa Pharmaceuticals Stock Performance
Shares of NASDAQ CNTA opened at $40.50 on Monday. The company has a debt-to-equity ratio of 0.23, a current ratio of 9.53 and a quick ratio of 9.53. The firm has a market cap of $6.27 billion, a price-to-earnings ratio of -22.63 and a beta of 1.11. The stock’s fifty day moving average price is $40.14 and its two-hundred day moving average price is $33.76. Centessa Pharmaceuticals PLC Sponsored ADR has a one year low of $12.74 and a one year high of $40.56.
Wall Street Analyst Weigh In
Several brokerages have issued reports on CNTA. B. Riley Financial downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Wells Fargo & Company lowered shares of Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and increased their price objective for the company from $35.00 to $42.00 in a research report on Monday, April 20th. Leerink Partners cut shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and raised their target price for the stock from $36.00 to $40.00 in a research note on Wednesday, April 1st. Truist Financial cut shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 target price for the company. in a research note on Monday, April 13th. Finally, Guggenheim lowered shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, April 2nd. Four research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $41.33.
Get Our Latest Report on Centessa Pharmaceuticals
Centessa Pharmaceuticals Profile
Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.
Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.
Featured Stories
- Five stocks we like better than Centessa Pharmaceuticals
- RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
- These 4 Earnings Reports Expose the Market’s Growing Economic Divide
- Broadcom May Be the Biggest Winner From Alphabet’s Earnings
- Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit
Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
